Obudai Egeszsegugyi Centrum Kft.
- Address
- lock Available on a paid plan
Obudai Egeszsegugyi Centrum Kft.
Obudai Egeszsegugyi Centrum Kft. is a distinguished clinical research facility specializing in comprehensive Phase 3 therapeutic investigations across multiple therapeutic domains. The center demonstrates particular expertise in cardiovascular disease research, with extensive experience in evaluating novel anticoagulants, lipid-modifying therapies, and cardiovascular outcome studies, as well as significant capabilities in immunological and inflammatory disorders.
- Cardiovascular disease prevention and treatment, including atherosclerotic cardiovascular disease, atrial fibrillation management, and heart failure with reduced ejection fraction
- Rheumatologic and inflammatory conditions, including rheumatoid arthritis, axial spondyloarthritis, hidradenitis suppurativa, and atopic dermatitis
- Metabolic disorders and bone health, encompassing obesity with cardiovascular complications and post-menopausal osteoporosis
- Advanced biosimilar development and comparative efficacy studies
The center's research portfolio reflects a commitment to addressing major unmet medical needs through rigorous evaluation of innovative therapeutic agents, including novel oral and injectable medications, biosimilars, and combination therapies. Their expertise spans from traditional cardiovascular interventions to cutting-edge biological therapies targeting specific inflammatory pathways, positioning them as a versatile partner in multinational pharmaceutical development programs focused on chronic disease management and cardiovascular risk reduction.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Anthos Therapeutics Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Obudai Egeszsegugyi Centrum Kft.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis | Alfasigma S.p.A. | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.